Biological Products and Biotechnology Division, Spanish Medicines Agency, Madrid, Spain.
Int J Lab Hematol. 2013 Feb;35(1):38-45. doi: 10.1111/j.1751-553X.2012.01459.x. Epub 2012 Aug 2.
The determination of factor VIII (FVIII) potency in FVIII concentrates can be performed using both manual and automated methods. This work aimed to validate the use of the chromogenic kit Coamatic® FVIII (Chromogenix) on the automated ACL® Elite PRO analyzer for evaluating the potency of FVIII in commercial preparations in pharmaceutical analytical laboratories. After setting the activation and reading times to 2 min and 3 min, respectively, the validation parameters, according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline Q2 (R1), were as follows: linearity, expressed by the adjusted model: log (Absorbance) = 1.848 + 0.777∙log (Concentration), with r² = 0.998; accuracy was verified (P-value = 0.6959); and the coefficient of variation for repeatability and intermediate precision was ≤6.5%. The Coamatic® FVIII kit method has been adapted to the ACL Elite PRO analyzer with improved performance compared with a manual microplate method.
可以使用手动和自动化方法来测定 FVIII 浓缩物中的因子 VIII(FVIII)效价。本研究旨在验证在自动化 ACL® Elite PRO 分析仪上使用发色试剂盒 Coamatic® FVIII(Chromogenix)评估商业制剂中 FVIII 效价的方法,该方法可用于药物分析实验室。分别将激活和读取时间设置为 2 分钟和 3 分钟后,根据人用药物注册技术要求国际协调会议(ICH)Q2(R1)指南,验证参数如下:线性度,通过调整后的模型表示:log(吸光度)= 1.848 + 0.777∙log(浓度),r²= 0.998;准确性得到验证(P 值= 0.6959);重复性和中间精密度的变异系数≤6.5%。与手动微孔板方法相比,Coamatic® FVIII 试剂盒方法已适应 ACL Elite PRO 分析仪,性能得到改善。